We are Constructive.Bio. Together, we are using world-leading technology to rewrite genomes and create biomolecules that were previously unimaginable. Discover the future of drug discovery and biomanufacturing with us.
is a disruptive
[ 01 ] revolutionising biotechnology with two core pillars: whole genome writing and engineered translation.
[ 02 ]We are setting new standards in creating programmable biomolecules for next-generation therapeutics and industrial applications
Based on Jason Chin’s ground breaking research at the MRC-LMB in Cambridge and backed by a strong intellectual property portfolio.
At Constructive.Bio, we’re pioneering
a dual-technology platform
[ 01 ] that combines de-novo genome synthesis and engineered translation. Our patented Syn61 strain serves as the cornerstone, allowing us to expand the genetic code and create biomolecules with unparalleled fidelity and specificity
This unique approach opens new avenues in both
[ 02 ] therapeutics and industrial biomanufacturing. From revolutionising antibody drug conjugates to creating phage-resistant strains, our technology is the key to unlocking the next generation of bioproducts